NCT04646330 - A Trial of AK104 Plus Anlotinib in NSCLC | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

October 26, 2023

Study Completion Date

July 30, 2025

Conditions

NSCLC

Interventions

DRUG

AK104+anlotinib

Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.

DRUG

AK104+anlotinib

Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.

DRUG

AK104+anlotinib

Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.

Trial Locations (1)

Hunan cancer hospital, Changsha